ArticleSchizophrenia bulletin2026
The Association Between Psychotropic Medications and Cognitive Functioning in a Real-World Cohort of 869 Individuals with Schizophrenia.
Article in Schizophrenia bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The association between psychotropic medications and cognitive functioning in bipolar disorder.International journal of bipolar disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCognitive deficits are a central feature of schizophrenia for which there are not any established pharmacological treatments. Antipsychotics are the mainstay of schizophrenia therapy but the effects of these and other psychotropic medications on the cognitive functioning of people schizophrenia have not been extensively studied in routine real-world settings. STUDY
designA total of 869 people with schizophrenia receiving community-based care were assessed on a cognitive battery, the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). The machine-learning tool of partialing-out least absolute shrinkage and selection operator (LASSO) regression were used to examine the independent association between the RBANS total and index scores and receipt of individual psychotropic medications considering relevant demographic, clinical, and environmental covariates. In this cross-sectional study, we also examined the effects of medication dosage and some medication combinations. STUDY
resultsWe found that 4 medications, clozapine, quetiapine, benztropine, and oral haloperidol were each independently associated with significantly reduced cognitive scores compared with people not receiving these medications. Three of the 4 medications, clozapine, haloperidol, and benztropine, showed a significant dose-related relationship with total cognitive score. We also documented further reductions in cognitive functioning in people receiving some pair-wise combinations of these medications. Reduced memory was the domain most associated with these medications, especially among people receiving clozapine.
conclusionsPrescribers may consider minimizing doses and limiting the administration of combinations of the identified medications. Interventions should be further developed for people with schizophrenia to improve their cognitive functioning and quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.